ReviewCurrent treatment options in infectious diseases
Cytomegalovirus Treatment.
Review in Current treatment options in infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 76 citations in OpenAlex.
- Acute transverse myelitis in an immunocompetent patient: syphilis and cytomegalovirus-a case report.AME case reports · 2026Article
- Considering the Risks and Costs of Solid Organ Xenotransplantation.Advanced biology · 2025Article
- Article
- Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma.Case reports in medicine · 2023Article
- Synthesis of 1-[ω-(Bromophenoxy)alkyl]-3-Naphthalenylmethyl Uracil Derivatives and Their Analogues as Probable Inhibitors of Human Cytomegalovirus Replication.Doklady. Biochemistry and biophysics · 2022Article
- Development and pharmacokinetic evaluation of osmotically controlled drug delivery system of Valganciclovir HCl for potential application in the treatment of CMV retinitis.Drug delivery and translational research · 2022Article
- Article
- COVID-19-associated opportunistic infections: a snapshot on the current reports.Clinical and experimental medicine · 2022Review
- Rare cause of left eye floaters and blurred vision in an immunocompromised patient: acute retinal necrosis (ARN).BMJ case reports · 2022Article
- Imaging Approach to Pulmonary Infections in the Immunocompromised Patient.The Indian journal of radiology & imaging · 2022Review
- Cytomegalovirus retinitis in the highly active anti-retroviral therapy era.Annals of eye science · 2022Article
- Human cytomegalovirus protein RL1 degrades the antiviral factor SLFN11 via recruitment of the CRL4 E3 ubiquitin ligase complex.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Systemic cytomegalovirus masquerading as a colorectal mass in a patient with undiagnosed HIV/AIDS.IDCases · 2022Article
- Herpesvirus-Associated Encephalitis: an Update.Current tropical medicine reports · 2022Review
- In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients.Virusdisease · 2021Review
- A computational multi-targeting approach for drug repositioning for psoriasis treatment.BMC complementary medicine and therapies · 2021Article
- Pentostatin antagonizes the antiviral activity of MBX-2168 by inhibiting the biosynthesis of the active compound.Antiviral research · 2021Article
- Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.Journal of the Pediatric Infectious Diseases Society · 2020Article
- Human cytomegalovirus protein pUL36: A dual cell death pathway inhibitor.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Postsurgical skin ulcers caused by cytomegalovirus vasculopathy in a renal transplant recipient.JAAD case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In treating cytomegalovirus (CMV) infection, it is crucial to decide whether one is treating pre-emptively or if one is treating established disease. Disease may be further divided into viral syndrome and tissue-invasive disease. Generally, mild disease in immunosuppressed patients may be treated with oral valganciclovir. Treatment may also be started with valganciclovir for CMV retinitis in AIDS patients. In other tissue-invasive syndromes, starting with intravenous ganciclovir or foscarnet at full doses (adjusted for renal function) is preferred. Treatment at full doses should be continued until symptom resolution and until blood antigenemia (or DNAemia) is cleared. Patients receiving treatment must be closely monitored for side effects to the drugs, as well as for response. Drug-resistant CMV is a therapeutic challenge; combination therapy with both ganciclovir and foscarnet may be tried. In extreme cases, resorting to unconventional agents like leflunomide or maribavir may be necessary. Immune reconstitution, through reduction in immunosuppression, or the introduction of anti-retroviral therapy, should be attempted. CMX001 is a novel agent active against double-stranded viruses; thus far, resistance to CMX001 does not confer resistance to ganciclovir or foscarnet. Hence, prophylaxis or pre-emptive treatment with CMX001 may allow the use of ganciclovir or foscarnet for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.